Kyntra BIO, Inc.

KYNB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000921299

E

weakest fifth of 369 graded peers in healthcare

rank 355 of 369; percentile 96.2; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	E percentile 91.9
Solvency	D percentile 66.3
Growth and financing	D percentile 69.5
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $119.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	10 of 14
Graded from	filings received through Mar 16, 2026 242 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$3.71 2026-11-10; market equity $15.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

Kyntra Bio, Inc. ("Kyntra Bio" or the "Company") is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. In January 2026, the Company announced its rebranding from "FibroGen, Inc." to "Kyntra Bio, Inc.", representing the next step of its transformation and focus on oncology and associated rare disease indications. On January 8, 2026, the Company's common stock began trading under the new Nasdaq symbol "KYNB." We are developing FG-3246, a potential first-in-class antibody-drug conjugate ("ADC") targeting CD46, for the treatment of metastatic castration-resistant prostate cancer ("mCRPC") and potentially other cancers.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 91.9						
Gross profitability	4.9%	32.3%		84.3	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

required facts have no common fiscal period end					
Accruals ratio	112.7%	(6.6%)	99.6	800	2025-12-31
Gross margin stability, five years	17.6 pts	2.8 pts	91.7	242	2025-12-31
Solvency, sleeve percentile 66.3					
Twelve-month failure probability	1.46%	0.08%	82.1	247	2026-06-30
Altman Z double-prime	(45.53)	(0.35)	87.6	744	2025-12-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	(5.24x)	(4.51x)	42.9	78	2025-12-31
Current ratio	3.39x	2.95x	52.6	826	2025-12-31
Growth and financing, sleeve percentile 69.5					
Revenue growth, three-year compound	(64.2%)	10.1%	96.8	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(41.9%)	2.2%	96.8	694	2025-12-31
Net share issuance, one year	0.3%	2.5%	14.7	627	2026-02-28

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
350	Silo Pharma, Inc. (SILO)	94.8	E	dilution, degenerate inputs, distress
351	ALX Oncology Holdings Inc. (ALXO)	95.1	E	dilution, short runway, degenerate inputs, fortress balance sheet
352	VivoSim Labs, Inc. (VIVS)	95.4	E	dilution, late filer
353	Bolt Biotherapeutics, Inc. (BOLT)	95.7	E	short runway, distress
354	Biomerica Inc. (BMRA)	95.9	E	
355	Kyntra BIO, Inc. (KYNB)	96.2	E	
356	Pfizer Inc. (PFE)	96.5	E	
357	Dare Bioscience, Inc. (DARE)	96.7	E	dilution
358	Longeveron Inc. (LGVN)	97.0	E	short runway
359	Clene Inc. (CLNN)	97.3	E	dilution, distress
360	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(40.2%)	(1.9%)	22
Distance from 52-week high	(64.2%)	(30.8%)	17
EBIT to enterprise value	(118.0%)	(1.9%)	7
Free cash flow yield	(33.1%)	(1.0%)	18

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	(2.07)	0.28	1
Sales to price	0.44	0.29	61
Composite equity issuance, five years	10.0%	20.5%	39
Relative strength against the sector, log excess return	(0.68)	(0.19)	22

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$50.6M
Operating cash flow, four quarters	-$38.1M
Months of runway	16.0
Days since last periodic filing	92 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$122,593

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.4M	2025-12-31	2026-03-16	10-K	26-108346
2	cost of revenue	us-gaap:CostOfRevenue	$556,000	2025-12-31	2026-03-16	10-K	26-108346
3	assets	us-gaap:Assets	$119.6M	2025-12-31	2026-03-16	10-K	26-108346
4	net income	us-gaap:NetIncomeLoss	$183.5M	2025-12-31	2026-03-16	10-K	26-108346
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$4.8M	2025-12-31	2026-03-16	10-K	26-108346
6	assets	us-gaap:Assets	$214.5M	2024-12-31	2026-03-16	10-K	26-108346
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$29.6M	2024-12-31	2026-03-16	10-K	26-108346
8	cost of revenue	us-gaap:CostOfRevenue	$15.6M	2024-12-31	2026-03-16	10-K	26-108346
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$46.8M	2023-12-31	2025-03-17	10-K	25-040280
10	cost of revenue	us-gaap:CostOfRevenue	$4.0M	2023-12-31	2025-03-17	10-K	25-040280
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$140.7M	2022-12-31	2024-02-26	10-K	24-020161
12	cost of revenue	us-gaap:CostOfRevenue	$20.3M	2022-12-31	2024-02-26	10-K	24-020161
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$235.3M	2021-12-31	2024-02-26	10-K	24-020161
14	cost of revenue	us-gaap:CostOfRevenue	$12.9M	2021-12-31	2024-02-26	10-K	24-020161
15	current assets	us-gaap:AssetsCurrent	$99.1M	2025-12-31	2026-03-16	10-K	26-108346
16	current liabilities	us-gaap:LiabilitiesCurrent	$29.2M	2025-12-31	2026-03-16	10-K	26-108346
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.7B	2025-12-31	2026-03-16	10-K	26-108346
18	operating income	us-gaap:OperatingIncomeLoss	-$45.9M	2025-12-31	2026-03-16	10-K	26-108346
19	book equity	us-gaap:StockholdersEquity	-$30.0M	2025-12-31	2026-03-16	10-K	26-108346
20	liabilities	us-gaap:Liabilities	$115.1M	2025-12-31	2026-03-16	10-K	26-108346
21	interest expense	us-gaap:InterestExpense	$8.8M	2025-12-31	2026-03-16	10-K	26-108346
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$38,000	2025-12-31	2026-03-16	10-K	26-108346
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$138.0M	2024-12-31	2026-03-16	10-K	26-108346
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$266,000	2024-12-31	2026-03-16	10-K	26-108346
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$315.0M	2023-12-31	2025-03-17	10-K	25-040280
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2023-12-31	2025-03-17	10-K	25-040280

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$145.9M	2022-12-31	2024-02-26	10-K	24-020161
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.7M	2022-12-31	2024-02-26	10-K	24-020161
29	depreciation amortization	us-gaap:Depreciation	$713,000	2025-12-31	2026-03-16	10-K	26-108346
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$58.3M	2025-12-31	2026-03-16	10-K	26-108346
31	income tax	us-gaap:IncomeTaxExpenseBenefit	-$90,000	2025-12-31	2026-03-16	10-K	26-108346
32	current assets	us-gaap:AssetsCurrent	$196.5M	2024-12-31	2026-03-16	10-K	26-108346
33	current liabilities	us-gaap:LiabilitiesCurrent	$133.3M	2024-12-31	2026-03-16	10-K	26-108346
34	assets	us-gaap:Assets	$423.5M	2023-12-31	2025-03-17	10-K	25-040280
35	assets	us-gaap:Assets	$610.1M	2022-12-31	2024-02-26	10-K	24-020161
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,046,827	2026-02-28	2026-03-16	10-K	26-108346
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	100,916,956	2025-02-28	2025-03-17	10-K	25-040280

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.